{"success":true,"data":{"pressRelease":{"id":"17191","rtpr_id":"nACSsk1SNa","ticker":"PEPG","exchange":"NASDAQ","all_tickers":["PEPG"],"title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG","author":"ACCESSWIRE","published_at":"2026-05-01T14:00:00.848Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Pomerantz LLP is investigating claims on behalf of investors of PepGen\nInc. (\"PepGen\" or the \"Company\") (NASDAQ:PEPG). Such investors are advised to\ncontact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.\n\nThe investigation concerns whether PepGen and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://pr.report/l72r)\n\nOn March 4, 2026, PepGen announced in a press release that \"[t]he U.S. Food\nand Drug Administration (FDA) has placed a partial clinical hold on the\nFREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized,\nplacebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic\ndystrophy type 1 (DM1)\", stating that \"[t]he partial clinical hold questions\nraised by FDA relate to previously submitted preclinical pharmacology and\ntoxicology studies.\"\n\nOn this news, PepGen's stock price fell $1.25 per share, or 18.57%, to close\nat $5.50 per share on March 5, 2026.\n\nThen, on March 30, 2026, PepGen issued a press release announcing \"clinical\ndata from the 5 mg/kg multiple ascending dose cohort (MAD) of the ongoing\nPhase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1 (DM1).\"\nAlthough PepGen characterized the data as \"promising,\" analysts noted the lack\nof meaningful improvement in patients' handgrip strength or 10-meter walk/run\ntest.\n\nOn this news, PepGen's stock price fell $2.46 per share, or 58.16%, to close\nat $1.77 per share on March 31, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1163008)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACSsk1SNa","title":"INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG","author":"ACCESSWIRE","ticker":"PEPG","created":"2026-05-01T14:00:00.848Z","tickers":["PEPG"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 1,\n2026 / Pomerantz LLP is investigating claims on behalf of investors of PepGen\nInc. (\"PepGen\" or the \"Company\") (NASDAQ:PEPG). Such investors are advised to\ncontact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.\n\nThe investigation concerns whether PepGen and certain of its officers and/or\ndirectors have engaged in securities fraud or other unlawful business\npractices.\n\n[Click here for information about joining the class action]\n(https://pr.report/l72r)\n\nOn March 4, 2026, PepGen announced in a press release that \"[t]he U.S. Food\nand Drug Administration (FDA) has placed a partial clinical hold on the\nFREEDOM2-DM1 Phase 2 multiple ascending dose (MAD), randomized,\nplacebo-controlled clinical trial of PGN-EDODM1 in patients with myotonic\ndystrophy type 1 (DM1)\", stating that \"[t]he partial clinical hold questions\nraised by FDA relate to previously submitted preclinical pharmacology and\ntoxicology studies.\"\n\nOn this news, PepGen's stock price fell $1.25 per share, or 18.57%, to close\nat $5.50 per share on March 5, 2026.\n\nThen, on March 30, 2026, PepGen issued a press release announcing \"clinical\ndata from the 5 mg/kg multiple ascending dose cohort (MAD) of the ongoing\nPhase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1 (DM1).\"\nAlthough PepGen characterized the data as \"promising,\" analysts noted the lack\nof meaningful improvement in patients' handgrip strength or 10-meter walk/run\ntest.\n\nOn this news, PepGen's stock price fell $2.46 per share, or 58.16%, to close\nat $1.77 per share on March 31, 2026.\n\nPomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris,\nand Tel Aviv, is acknowledged as one of the premier firms in the areas of\ncorporate, securities, and antitrust class litigation. Founded by the late\nAbraham L. Pomerantz, known as the dean of the class action bar, Pomerantz\npioneered the field of securities class actions. Today, more than 85 years\nlater, Pomerantz continues in the tradition he established, fighting for the\nrights of the victims of securities fraud, breaches of fiduciary duty, and\ncorporate misconduct. The Firm has recovered numerous multimillion-dollar\ndamages awards on behalf of class members. See www.pomlaw.com.\n\nAttorney advertising. Prior results do not guarantee similar outcomes.\n\nSOURCE: Pomerantz LLP\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1163008)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-01T14:00:00.882002714Z","server_sent_at_ms":1777644000882},"received_at":"2026-05-01T14:00:01.287Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-1163008"},"analysis":{"id":"12660","press_release_id":"17191","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Pomerantz LLP announced an investigation into potential securities fraud by PepGen Inc. and its officers.\n\nThe firm cites the March 4 FDA partial clinical hold on PGN-EDODM1 and subsequent analyst criticism of March 30 clinical data as catalysts.\n\nThis is a solicitation for investors to join a class action, not a disclosure from PepGen itself.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{},"quotedText":"investigating claims on behalf of investors of PepGen Inc.","namedEntities":{"people":[{"name":"Danielle Peyton","role":"Contact"}],"products":["PGN-EDODM1"],"companies":[{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"PepGen Inc.","ticker":"PEPG","relationship":"target"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$1.25","context":"stock price drop on March 5, 2026"},{"amount":"$2.46","context":"stock price drop on March 31, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Pomerantz LLP. No new disclosure from the issuer; no certified class, no settlement. Boilerplate investigation announcement."},"tickerRelevance":{"others":[],"primary":"PEPG"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Pomerantz LLP announced an investigation into potential securities fraud by PepGen Inc. and its officers.\n\nThe firm cites the March 4 FDA partial clinical hold on PGN-EDODM1 and subsequent analyst criticism of March 30 clinical data as catalysts.\n\nThis is a solicitation for investors to join a class action, not a disclosure from PepGen itself.","key_figures":{},"named_entities":{"people":[{"name":"Danielle Peyton","role":"Contact"}],"products":["PGN-EDODM1"],"companies":[{"name":"Pomerantz LLP","relationship":"plaintiff law firm"},{"name":"PepGen Inc.","ticker":"PEPG","relationship":"target"},{"name":"U.S. Food and Drug Administration","relationship":"regulator"}],"dollarAmounts":[{"amount":"$1.25","context":"stock price drop on March 5, 2026"},{"amount":"$2.46","context":"stock price drop on March 31, 2026"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-01T14:32:40.033Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":29452,"modelName":"glm-4.7"}}